News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
marketbeat.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
vTv Therapeutics Inc. has reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin, a treatment for type 1 diabetes, in Q3 2026 …
vTv Therapeutics announced its Q2 2026 financial results, reporting a net loss of $13.1 million but maintaining sufficient cash to fund operations through the anticipated topline data readout of its Phase 3 CATT1 trial. Enrollment for the CATT1 trial, which evaluates cadisegliatin for type …
Millennium-affiliated entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have filed an amended Schedule 13G/A disclosing their beneficial ownership in vTv Therapeutics Inc. (VTVT) Class A common stock. Integrated Core Strategies (US) LLC reports …
This article provides a revenue breakdown for vTv Therapeutics, Inc. Class A (SWB:5VT0) listed on the Stuttgart Stock Exchange. It indicates fundamental and statistical information, including statements, dividends, earnings, and segment performance. The content is presented without specific financial figures, focusing on the available …
Search by ticker symbol or company name and select a result to open its chart.